6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 75 mg) Pathway Feedback Search Clinical Topics Home Studies OCEAN(a)-DOSE (olpasiran 75 mg) OCEAN(a)-DOSE (olpasiran 75 mg) Disease Disease Disease Acute ischemic stroke Coronary artery disease Dyslipidem Trial question What is the role of olpasiran in patients with established ASCVD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 37.0% female N = 112 63.0% male 112 patients (41 female, 71 male) Inclusion criteria: patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L Key exclusion criteria: severe renal dysfunction or active liver disease Interventions N=58 olpasiran (at a dose of 75 mg every 12 week) N=54 placebo (matching placebo every 12 week) Primary outcome https://web.pathway.md/studies/recyrSaylmuV2Nd3s 1/2 6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 75 mg) Pathway Significant increase in percent reduction in lipoprotein(a) concentration at week 36 (93.8% vs. -3.6%; AD 97.4%, 95% CI 92.8 to 102) Secondary outcomes Significant increase in percent reduction in low-density lipoprotein cholesterol at week 36 (16.3% vs. -6.3%; AD 22.6%, 95% CI 11 to 34.1) Significant increase in percent reduction in ApoB concentration at week 36 (9.3% vs. -7.4%; AD 16.7%, 95% CI 9.3 to 24.1) Safety outcomes No significant difference in adverse and serious adverse events. Conclusion In patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L, olpasiran was superior to placebo with respect to percent reduction in lipoprotein(a) concentration at week 36. Reference Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. Open reference URL https://web.pathway.md/studies/recyrSaylmuV2Nd3s 2/2